Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an update.
Shanghai Junshi Biosciences Co., Ltd. has announced a change in the book closure period and record date for its 2024 Annual General Meeting (AGM). The book closure period, initially set from June 13 to June 20, 2025, has been revised to end on June 19, 2025, with the record date also moved to June 19, 2025. This adjustment ensures that shareholders listed by the end of June 19, 2025, are eligible to attend and vote at the AGM, aligning with the company’s efforts to maintain transparent and efficient shareholder engagement.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biotechnology company based in China, focusing on the development and commercialization of innovative drugs, particularly in the field of oncology and autoimmune diseases. The company is known for its research and development capabilities and its market focus on providing advanced therapeutic solutions.
Average Trading Volume: 5,639,768
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.14B
See more insights into 1877 stock on TipRanks’ Stock Analysis page.